ahlam1399
06-27-2016, 01:13 PM
UPDATE 1-Allergy Therapeutics says study fails to find hay fever therapy dose range
June 27 (Reuters) – Drug developer Allergy Therapeutics Plc
said a study on suitable doses of its therapy to treat
grass allergic rhinitis, or hay fever, did **t find a
recommended dose for a late-stage trial.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=xlgrpvw-zXs:FxNYfK-v5aw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=xlgrpvw-zXs:FxNYfK-v5aw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=xlgrpvw-zXs:FxNYfK-v5aw:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=xlgrpvw-zXs:FxNYfK-v5aw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=xlgrpvw-zXs:FxNYfK-v5aw:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/xlgrpvw-zXs
June 27 (Reuters) – Drug developer Allergy Therapeutics Plc
said a study on suitable doses of its therapy to treat
grass allergic rhinitis, or hay fever, did **t find a
recommended dose for a late-stage trial.http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=xlgrpvw-zXs:FxNYfK-v5aw:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=xlgrpvw-zXs:FxNYfK-v5aw:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=xlgrpvw-zXs:FxNYfK-v5aw:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=xlgrpvw-zXs:FxNYfK-v5aw:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=xlgrpvw-zXs:FxNYfK-v5aw:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/xlgrpvw-zXs